Shares of Ernexa Therapeutics (ERNA) skyrocketed 58.5% to $11.43 on Tuesday, driven by a surge of investor interest in its preclinical ovarian-cancer cell therapy, ERNA-101. The stock traded in a wide range between $6.86 and $15.58, with volume reaching approximately 18.85 million shares, a classic biotech squeeze scenario fueled by a limited float and a recent reverse stock split.
The catalyst was a May 11 Virtual Investor KOL Connect event, where Chief Scientific Officer Dr. Robert Pierce presented the company's approach to treating ovarian cancer. Pierce highlighted ERNA-101's potential to convert immunologically "cold" tumors into "hot," immune-active targets, making them more vulnerable to attack. The company also reported preclinical data on May 6 showing that ERNA-101 combined with a PD-1 blockade resulted in complete tumor elimination and 100% long-term survival in mouse models. While these are animal data, not human results, such outcomes can trigger significant repricing in microcap biotech stocks.
The excitement is set to continue with a May 13 Virtual Investor Closing Bell event featuring CEO Sanjeev Luther and Dr. Pierce, keeping the spotlight on ERNA-101. The company has outlined milestones including an Investigational New Drug (IND) filing in Q3 2026 and a Phase 1 trial targeting platinum-resistant ovarian cancer in Q4 2026.
However, funding remains a critical concern. Ernexa reported $8.3 million in cash as of April 30, down from $9.2 million on March 31, which is insufficient to cover its operating plan for the next 12 months. The company may turn to its at-the-market (ATM) stock sale program to raise additional capital, a move that could dilute existing shareholders. This dilution risk is a key factor for investors to weigh against the potential upside of ERNA-101.
The company's first-quarter results, released without an official earnings call, showed a net loss of $5.5 million, improved from $8.2 million a year earlier, but operating expenses more than doubled to $5.59 million, including a $2.04 million goodwill impairment. Loss per share narrowed dramatically to $6.95 from $57.76, partly due to the reverse split.
The 1-for-25 reverse split, effective May 4, was implemented to meet Nasdaq's $1 minimum bid requirement. While it boosts the stock price mechanically, it reduces the share count and can amplify price swings, as seen in Tuesday's volatile trading.
Ernexa operates in a landscape where cell therapies are gaining regulatory traction. Iovance's Amtagvi and Adaptimmune's Tecelra have received FDA approvals for solid tumors, and Verastem's avutometinib-defactinib combo earned accelerated approval in 2025 for KRAS-mutated ovarian cancer. However, these programs are far ahead in clinical development, and Ernexa's path to human data remains uncertain.
Bulls see ERNA-101 as a potential first-in-human candidate by year-end, while bears focus on the company's cash burn, dilution risk, and the gap between promising mouse data and effective human therapies. Tuesday's rally may have lifted sentiment, but it also increases the likelihood of share sales to fund the next trial phase.
